Inactive Instrument

Alliance Pharma plc

APH

GB0031030819

Alliance Pharma : RBC Initiates Alliance Pharma at Outperform

Published on 03/29/2021 at 03:39 pm BST - Modified on 03/29/2021 at 05:15 pm BST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Alliance Pharma plc

15/05/25	Alliance Pharma Delists from London Bourse's AIM After Acquisition	MT
14/05/25	Aegros Bidco Completes Takeover of Alliance Pharma	MT
14/05/25	Alliance Pharma Says Aegros Bidco Recommends Acquisition Of Alliance Pharma	RE
13/05/25	Alliance Pharma plc Announces the Termination of Camillo Pane as Director, Effective May 14, 2025	CI
13/05/25	Alliance Pharma plc Announces the Termination of Mr. Richard Alexander Mckenzie as Director, Effective from May 14, 2025	CI
13/05/25	Alliance Pharma Plc Announces the Termination of Martin Sutherland as Director, Effective May 14, 2025	CI
13/05/25	Alliance Pharma plc Announces the Termination of Kristof Leon Neirynck as Director, Effective from May 14, 2025	CI
13/05/25	Alliance Pharma plc Announces the Termination of Richard Crispin Jones as Director, Effective from May 14, 2025	CI
13/05/25	Alliance Pharma Plc Announces the Termination of Eva-Lotta Saga Sjostedt as Director, Effective May 14, 2025	CI
13/05/25	An undisclosed funds, managed by DBAY Advisors Limited, An undisclosed funds, managed by Baring Asset Management Limited, Edmond De Rothschild Equity Strategies IV Fund, a fund managed by Edmond de Rothschild Private Equity Management Ltd. and an undisclosed buyer completed the acquisition of remaining 71.9% stake in Alliance Pharma plc from Andrew Franklin, Richard Jones, Nick Sedgwick, Slater Investments Limited and others.	CI
13/05/25	Aegros' Takeover of Alliance Pharma Sanctioned by Court	MT
29/04/25	Slater Investments Discloses 4.37% Stake In Alliance Pharma As Of 25-Apr-2025	RE
08/04/25	Alliance Pharma loss narrows in 2024 due to reduced impairment charges	AN
08/04/25	Alliance Pharma Says Group Performance In Three Months To End March In-Line With Expectations	RE
08/04/25	Alliance Pharma plc Reports Earnings Results for the Full Year Ended December 31, 2024	CI

Alliance Pharma plc is a United Kingdom-based international consumer healthcare company. The principal activity of the Company is to act as a holding company. The principal activity of the Company is the acquisition, marketing and distribution of consumer healthcare and pharmaceutical products. Its segments include Consumer Healthcare brands and Prescription Medicines. Its Consumer Healthcare brands include the Kelo-Cote franchise, Amberen, Nizoral, MacuShield, Aloclair, Vamousse, and other consumer healthcare brands. Its Prescription Medicines include Hydromol, Flamma Franchise, Forceval and other prescription medicines. Its products include Aloclair Plus Gel, Aloclair Plus Spray, Aloclair Plus Mouthwash, Anbesol Adult Strength Gel, Anbesol Teething Gel, Anbesol Liquid, Atopiclair Cream, and Atopiclair Lotion. It holds marketing rights to around 80 consumer healthcare brands and prescription medicines, which are sold worldwide in more than 100 countries.

Employees

290

Sector

Pharmaceuticals

More about the company